Srinivas B. Muvvala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Srinivas B. Muvvala has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Jeanette M. Tetrault
Program in Addiction Medicine, Yale School of Medicine, New Haven, CT, USA
2 shared publications- John Encandela
Program in Addiction Medicine, Yale School of Medicine, New Haven, CT (SBM, RM, EB, KLM, JE, JMT)
2 shared publications - Stephanie S. O'MAlley
Department of Psychiatry Yale School of Medicine New Haven Connecticut USA
2 shared publications Akhil Anand
Department of Psychiatry and Psychology, Cleveland Clinic, OH, USA
1 shared publication- Allen Zweben
School of Social Work, Columbia University, New York, New York, USA
1 shared publication - Carla Marienfeld
Department of Psychiatry, University of California San Diego, San Diego, USA
1 shared publication
Latest Publications
- 2 November 2026
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
Development of an Interprofessional Teamwork Entrustable Professional Activity for Addiction Medicine and Addiction Psychiatry Fellows
Background: Substance-use disorders (SUD) require collaborative, multi-specialty care. While graduate medical education (GME) fellowships in addiction medicine (AM) and addiction psychiatry (AP) prepare trainees for interprofessional collaborative care, standard Accreditation Council for Graduate Medical Education milestones lack a mechanism to directly observe and assess competence in providing interprofessional team-based care. Objective: To develop and pilot an entrustable professional activity (EPA) focused on interprofessional team-based care applicable to both AM and AP fellowships. Methods: Using a systematic 3-step consensus process, a multidisciplinary faculty team mapped overlapping AM and AP milestones across 6 Accreditation Council for Graduate Medical Education core domains to identify those related to interprofessional work. Key functions and a scoring instrument to measure them were developed by an iterative consensus process. The team then drafted an Interprofessional EPA listing foundational milestones and related functions alongside descriptions of expected behaviors at 3 developmental levels. Results: The EPA was piloted with faculty and fellows. Initial implementation faced barriers regarding faculty uptake due to competing demands. Based on faculty feedback, the EPA was transitioned from a summative scale to a formative tool utilizing narrative summaries to enhance real-time feedback and support milestone reporting. Conclusions: This EPA provides a structured approach to assess essential, observable interprofessional clinical skills. By shifting to a formative framework, the tool facilitates low-stakes feedback and fosters cross-disciplinary learning. As there is a national push to incorporate EPAs into trainee assessments, this process can inform other residency and fellowship training programs nationally in implementing similar frameworks.
- 2 November 2026
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
Development of an Interprofessional Teamwork Entrustable Professional Activity for Addiction Medicine and Addiction Psychiatry Fellows
Background: Substance-use disorders (SUD) require collaborative, multi-specialty care. While graduate medical education (GME) fellowships in addiction medicine (AM) and addiction psychiatry (AP) prepare trainees for interprofessional collaborative care, standard Accreditation Council for Graduate Medical Education milestones lack a mechanism to directly observe and assess competence in providing interprofessional team-based care. Objective: To develop and pilot an entrustable professional activity (EPA) focused on interprofessional team-based care applicable to both AM and AP fellowships. Methods: Using a systematic 3-step consensus process, a multidisciplinary faculty team mapped overlapping AM and AP milestones across 6 Accreditation Council for Graduate Medical Education core domains to identify those related to interprofessional work. Key functions and a scoring instrument to measure them were developed by an iterative consensus process. The team then drafted an Interprofessional EPA listing foundational milestones and related functions alongside descriptions of expected behaviors at 3 developmental levels. Results: The EPA was piloted with faculty and fellows. Initial implementation faced barriers regarding faculty uptake due to competing demands. Based on faculty feedback, the EPA was transitioned from a summative scale to a formative tool utilizing narrative summaries to enhance real-time feedback and support milestone reporting. Conclusions: This EPA provides a structured approach to assess essential, observable interprofessional clinical skills. By shifting to a formative framework, the tool facilitates low-stakes feedback and fosters cross-disciplinary learning. As there is a national push to incorporate EPAs into trainee assessments, this process can inform other residency and fellowship training programs nationally in implementing similar frameworks.
- 15 July 2026
- Published by SAGE Publications in Substance use & addiction journal
Addiction Specialists’ Knowledge About and Assessment Practices for Kratom, Phenibut, and Tianeptine
Background: Kratom, phenibut, and tianeptine are marketed as “nootropics” or cognitive enhancers but carry significant risk for misuse and addiction. Their widespread availability through internet and retail outlets, where they are often illegally marketed as dietary supplements, allows them to bypass regulatory oversight. We evaluated the knowledge, attitudes, and clinical practices of attendees at a national addiction conference regarding these little-known emerging substances. Methods: We conducted a cross-sectional, 46-item web survey of attendees at a national addiction conference attending a dedicated nootropics session. Items assessed self-reported knowledge, perceived patient use, assessment practices, and opinions on regulation regarding kratom, phenibut, and tianeptine. Responses were collected using Qualtrics and rated on 5-point Likert scales. Chi-square tests examined exploratory subgroup differences. Results: Thirty-four of 59 eligible attendees responded (34/59, 57.6%). Most were physicians (31/34, 91%) and female (18/34, 53%). Most (21/34, 61.8%) reported limited knowledge about nootropics, particularly regarding phenibut (22/34, 64.7%) and tianeptine (20/34, 58.8%). Despite limited self-assessments of knowledge, most respondents were concerned about the accessibility of kratom, phenibut, and tianeptine (31/34, 91.2%) and their use among patients (23/34, 67.6%). The majority also supported stronger regulatory oversight (24/34, 70.6%) and almost all endorsed the need for further research (33/34, 97.1%). Conclusions: Surveyed respondents attending a dedicated nootropics session at an addiction conference reported substantial knowledge gaps about kratom, phenibut, and tianeptine, yet consistently endorsed the need for greater regulation and research. Clinical assessment practices and educational strategies warrant further study.
- 15 July 2026
- Published by SAGE Publications in Substance use & addiction journal
Addiction Specialists’ Knowledge About and Assessment Practices for Kratom, Phenibut, and Tianeptine
Background: Kratom, phenibut, and tianeptine are marketed as “nootropics” or cognitive enhancers but carry significant risk for misuse and addiction. Their widespread availability through internet and retail outlets, where they are often illegally marketed as dietary supplements, allows them to bypass regulatory oversight. We evaluated the knowledge, attitudes, and clinical practices of attendees at a national addiction conference regarding these little-known emerging substances. Methods: We conducted a cross-sectional, 46-item web survey of attendees at a national addiction conference attending a dedicated nootropics session. Items assessed self-reported knowledge, perceived patient use, assessment practices, and opinions on regulation regarding kratom, phenibut, and tianeptine. Responses were collected using Qualtrics and rated on 5-point Likert scales. Chi-square tests examined exploratory subgroup differences. Results: Thirty-four of 59 eligible attendees responded (34/59, 57.6%). Most were physicians (31/34, 91%) and female (18/34, 53%). Most (21/34, 61.8%) reported limited knowledge about nootropics, particularly regarding phenibut (22/34, 64.7%) and tianeptine (20/34, 58.8%). Despite limited self-assessments of knowledge, most respondents were concerned about the accessibility of kratom, phenibut, and tianeptine (31/34, 91.2%) and their use among patients (23/34, 67.6%). The majority also supported stronger regulatory oversight (24/34, 70.6%) and almost all endorsed the need for further research (33/34, 97.1%). Conclusions: Surveyed respondents attending a dedicated nootropics session at an addiction conference reported substantial knowledge gaps about kratom, phenibut, and tianeptine, yet consistently endorsed the need for greater regulation and research. Clinical assessment practices and educational strategies warrant further study.
- 27 April 2025
- Published by SAGE Publications in Substance Abuse
- Vol. 46 (4) , 1013-1018
Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program
Background: Substance use is a major global public health challenge. A well-trained health care workforce is needed to prevent, address, and treat substance use disorders (SUD) internationally. Methods: In September 2021, the Yale Schools of Medicine (YSM) and Public Health (YSPH) and the University of Jordan (UJ) collaborated to establish the Yale-UJ Joint Training Program in Addiction Medicine. The curriculum was developed using the six-step Kern Model. The program aimed to create opportunities for cross-cultural, interprofessional education in addiction medicine to address education and treatment gaps. Results: The two-year program led to novel learning, training, and research opportunities in addiction medicine for faculty, staff, and students at YSM, YSPH, and UJ. The program implemented 16 lectures, a live in-person training workshop, three student-led discussion events, a student-led exchange network, a novel elective course, two cross-institutional research projects, and resulted in three published peer reviewed articles, two international conference presentations, three elective training opportunities, and one postdoctoral training. The program was well received by students and faculty and resulted in SUD treatment stakeholder collaboration in both countries. Conclusions: Establishment of a cross-national, interprofessional joint training program creates opportunities to implement novel education, research, and mentorship to prepare a culturally informed workforce.
- 27 April 2025
- Published by SAGE Publications in Substance Abuse
- Vol. 46 (4) , 1013-1018
Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program
Background: Substance use is a major global public health challenge. A well-trained health care workforce is needed to prevent, address, and treat substance use disorders (SUD) internationally. Methods: In September 2021, the Yale Schools of Medicine (YSM) and Public Health (YSPH) and the University of Jordan (UJ) collaborated to establish the Yale-UJ Joint Training Program in Addiction Medicine. The curriculum was developed using the six-step Kern Model. The program aimed to create opportunities for cross-cultural, interprofessional education in addiction medicine to address education and treatment gaps. Results: The two-year program led to novel learning, training, and research opportunities in addiction medicine for faculty, staff, and students at YSM, YSPH, and UJ. The program implemented 16 lectures, a live in-person training workshop, three student-led discussion events, a student-led exchange network, a novel elective course, two cross-institutional research projects, and resulted in three published peer reviewed articles, two international conference presentations, three elective training opportunities, and one postdoctoral training. The program was well received by students and faculty and resulted in SUD treatment stakeholder collaboration in both countries. Conclusions: Establishment of a cross-national, interprofessional joint training program creates opportunities to implement novel education, research, and mentorship to prepare a culturally informed workforce.
- 16 June 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (6) , e388-e391
Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Background: Integrated addiction treatment in HIV clinics is associated with improved outcomes, yet it is offered inconsistently and with variable models of care. We sought to evaluate the impact of Implementation Facilitation (“Facilitation”) on clinician and staff preference for provision of addiction treatment in HIV clinics with on-site resources (all trained or designated on-site specialist) versus outside resources (outside specialist or refer out). Methods: From July 2017 to July 2020, surveys assessed clinician and staff preferences for addiction treatment models during control (ie, baseline), intervention, evaluation, and maintenance phases in 4 HIV clinics in the Northeast United States. Results: During the control phase, among 76 respondents (response rate, 58%), the proportions who preferred treatment with on-site resources for opioid use disorder (OUD), alcohol use disorder (AUD), and tobacco use disorder (TUD) were 63%, 55%, and 63%, respectively. Compared with control, there were no significant differences in preferred model during the intervention and evaluation phases except for AUD where there was an increased preference for treatment with on-site resources in the intervention versus control phase. Compared with control, during the maintenance phase, a higher proportion of clinicians and staff preferred providing addiction treatment with on-site resources versus outside resources: OUD, 75% (odds ratio [OR; 95% confidence interval {CI}], 1.79 [1.06–3.03]); AUD, 73% (OR [95% CI], 2.23 [1.36–3.65]), and TUD, 76% (OR [95% CI], 1.88 [1.11–3.18]). Conclusions: The findings from this study lend support for “Facilitation” as a strategy to enhance clinician and staff preference for integrated addiction treatment in HIV clinics with on-site resources.
- 16 June 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (6) , e388-e391
Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Background: Integrated addiction treatment in HIV clinics is associated with improved outcomes, yet it is offered inconsistently and with variable models of care. We sought to evaluate the impact of Implementation Facilitation (“Facilitation”) on clinician and staff preference for provision of addiction treatment in HIV clinics with on-site resources (all trained or designated on-site specialist) versus outside resources (outside specialist or refer out). Methods: From July 2017 to July 2020, surveys assessed clinician and staff preferences for addiction treatment models during control (ie, baseline), intervention, evaluation, and maintenance phases in 4 HIV clinics in the Northeast United States. Results: During the control phase, among 76 respondents (response rate, 58%), the proportions who preferred treatment with on-site resources for opioid use disorder (OUD), alcohol use disorder (AUD), and tobacco use disorder (TUD) were 63%, 55%, and 63%, respectively. Compared with control, there were no significant differences in preferred model during the intervention and evaluation phases except for AUD where there was an increased preference for treatment with on-site resources in the intervention versus control phase. Compared with control, during the maintenance phase, a higher proportion of clinicians and staff preferred providing addiction treatment with on-site resources versus outside resources: OUD, 75% (odds ratio [OR; 95% confidence interval {CI}], 1.79 [1.06–3.03]); AUD, 73% (OR [95% CI], 2.23 [1.36–3.65]), and TUD, 76% (OR [95% CI], 1.88 [1.11–3.18]). Conclusions: The findings from this study lend support for “Facilitation” as a strategy to enhance clinician and staff preference for integrated addiction treatment in HIV clinics with on-site resources.
- 17 August 2020
- Published by Wiley in The American Journal on Addictions
- Vol. 30 (1) , 55-64
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder
Background and Objectives: Despite substantial evidence of the efficacy of naltrexone in treating alcohol use disorder (AUD), naltrexone is used infrequently and often for short durations. Understanding factors related to the initiation and continued use of naltrexone could identify targets for improving its use in clinical practice.Methods: We used the Fiscal year 2012 national data from the Veterans Health Administration to identify the proportion of veterans diagnosed with AUD who initiated and then continued to receive naltrexone for AUD over a 6‐month period (N = 67,788). We further examined correlates of any use and continued use, and patterns of use in inpatient and outpatient mental health services and psychotropic prescription fills. Comparisons were made using bivariate analyses and multinomial logistic regression.Results: Among the veterans diagnosed with AUD, 2.02% initiated treatment with naltrexone. Naltrexone initiation was associated with recent homelessness, concurrent psychiatric disorders, receipt of psychiatric outpatient services, psychotropic prescription fills, residential treatment, and psychiatric and medical‐surgical hospitalization. Of the 1,366 patients initiating naltrexone, 43.2% (590) received 2 to 5 prescriptions and 16.3% (223) received more than 5 prescriptions for naltrexone. Use of naltrexone beyond one prescription was associated with homelessness, major depressive disorder, schizophrenia, psychotropic medication use, and psychiatric hospitalization.Conclusion: Veterans with AUD who used and continued naltrexone were primarily those with multimorbidity and extensive involvement in psychiatric treatment.Scientific Significance: Prior studies examined the correlates of initiation of naltrexone but retention in treatment has received less attention. This study identified the frequency and important patient and service correlates of continued use of naltrexone. (Am J Addict 2021;30:55–64)
- 17 August 2020
- Published by Wiley in The American Journal on Addictions
- Vol. 30 (1) , 55-64
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder
Background and Objectives: Despite substantial evidence of the efficacy of naltrexone in treating alcohol use disorder (AUD), naltrexone is used infrequently and often for short durations. Understanding factors related to the initiation and continued use of naltrexone could identify targets for improving its use in clinical practice.Methods: We used the Fiscal year 2012 national data from the Veterans Health Administration to identify the proportion of veterans diagnosed with AUD who initiated and then continued to receive naltrexone for AUD over a 6‐month period (N = 67,788). We further examined correlates of any use and continued use, and patterns of use in inpatient and outpatient mental health services and psychotropic prescription fills. Comparisons were made using bivariate analyses and multinomial logistic regression.Results: Among the veterans diagnosed with AUD, 2.02% initiated treatment with naltrexone. Naltrexone initiation was associated with recent homelessness, concurrent psychiatric disorders, receipt of psychiatric outpatient services, psychotropic prescription fills, residential treatment, and psychiatric and medical‐surgical hospitalization. Of the 1,366 patients initiating naltrexone, 43.2% (590) received 2 to 5 prescriptions and 16.3% (223) received more than 5 prescriptions for naltrexone. Use of naltrexone beyond one prescription was associated with homelessness, major depressive disorder, schizophrenia, psychotropic medication use, and psychiatric hospitalization.Conclusion: Veterans with AUD who used and continued naltrexone were primarily those with multimorbidity and extensive involvement in psychiatric treatment.Scientific Significance: Prior studies examined the correlates of initiation of naltrexone but retention in treatment has received less attention. This study identified the frequency and important patient and service correlates of continued use of naltrexone. (Am J Addict 2021;30:55–64)
- 25 May 2020
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 44 (7) , 1431-1443
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Background: The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders. Yet, its prospective association with craving and naturalistic drinking outcomes in clinical trials remains unknown. This study embedded repeated human laboratory assessments of alcohol cue reactivity within the context of a randomized controlled trial to examine the effects of varenicline tartrate (Chantix®), a partial agonist of α4β2 nicotinic acetylcholine receptors, on alcohol craving among treatment‐seeking heavy drinkers with AUD. Our main objectives were to test whether varenicline, as compared to placebo, blunts alcohol cue–elicited craving and test whether alcohol cue reactivity observed in the human laboratory predicts subsequent alcohol craving and use during the remainder of the trial.Design and Methods: This double‐blind, randomized, 2‐site study compared the effects of varenicline (up to 2 mg/d) and placebo on responses to in vivo alcohol cue and affective picture cue exposure in the human laboratory. Forty‐seven volunteers (18 females, 29 males), ages 23 to 67 years (M = 43.7, SD = 11.5), were recruited from the community via advertisements to participate in a clinical trial designed to study the effects of varenicline on alcohol use. Participants were randomized to either varenicline or placebo for 6 weeks.Results: Varenicline did not attenuate cue‐induced alcohol craving relative to placebo, but craving captured during the cue reactivity paradigm significantly predicted subsequent alcohol use in real‐world settings during the clinical trial. Higher craving predicted heavier alcohol use.Conclusions: Our results are among the first to show alcohol cue–induced craving captured during a human laboratory paradigm predicts drinking outcomes in the context of a clinical trial.
- 25 May 2020
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 44 (7) , 1431-1443
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Background: The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders. Yet, its prospective association with craving and naturalistic drinking outcomes in clinical trials remains unknown. This study embedded repeated human laboratory assessments of alcohol cue reactivity within the context of a randomized controlled trial to examine the effects of varenicline tartrate (Chantix®), a partial agonist of α4β2 nicotinic acetylcholine receptors, on alcohol craving among treatment‐seeking heavy drinkers with AUD. Our main objectives were to test whether varenicline, as compared to placebo, blunts alcohol cue–elicited craving and test whether alcohol cue reactivity observed in the human laboratory predicts subsequent alcohol craving and use during the remainder of the trial.Design and Methods: This double‐blind, randomized, 2‐site study compared the effects of varenicline (up to 2 mg/d) and placebo on responses to in vivo alcohol cue and affective picture cue exposure in the human laboratory. Forty‐seven volunteers (18 females, 29 males), ages 23 to 67 years (M = 43.7, SD = 11.5), were recruited from the community via advertisements to participate in a clinical trial designed to study the effects of varenicline on alcohol use. Participants were randomized to either varenicline or placebo for 6 weeks.Results: Varenicline did not attenuate cue‐induced alcohol craving relative to placebo, but craving captured during the cue reactivity paradigm significantly predicted subsequent alcohol use in real‐world settings during the clinical trial. Higher craving predicted heavier alcohol use.Conclusions: Our results are among the first to show alcohol cue–induced craving captured during a human laboratory paradigm predicts drinking outcomes in the context of a clinical trial.
- 17 January 2020
- Published by SAGE Publications in Substance Abuse
- Vol. 41 (4) , 475-479
Stitching A Solution to the Addiction Epidemic: A Longitudinal Addiction Curricular Thread across Four Years of Medical Training
Background: Despite the enormous burden and public health impact, addiction continues to be one of the most under-treated chronic diseases primarily because of the lack of adequately trained work force of medical providers. To address this issue, medical schools should greatly expand education on addiction. Methods: The six-step Kern model of curriculum development was used as a framework to create an addiction curriculum which includes didactic activities, workshop exercises, practice-based learning activities, clinical simulations, and clinical experiences. Results: The authors and other members of the addiction thread committee conducted a comprehensive needs assessment, developed curriculum goals and objectives, and worked with course and clerkship directors to develop and enhance educational strategies and implement a longitudinal curricular thread woven across all four years of medical school curriculum. Conclusion: Development and implementation of a comprehensive addiction curriculum is feasible, and this model could lay the ground work for implementation at other institutions.
- 17 January 2020
- Published by SAGE Publications in Substance Abuse
- Vol. 41 (4) , 475-479
Stitching A Solution to the Addiction Epidemic: A Longitudinal Addiction Curricular Thread across Four Years of Medical Training
Background: Despite the enormous burden and public health impact, addiction continues to be one of the most under-treated chronic diseases primarily because of the lack of adequately trained work force of medical providers. To address this issue, medical schools should greatly expand education on addiction. Methods: The six-step Kern model of curriculum development was used as a framework to create an addiction curriculum which includes didactic activities, workshop exercises, practice-based learning activities, clinical simulations, and clinical experiences. Results: The authors and other members of the addiction thread committee conducted a comprehensive needs assessment, developed curriculum goals and objectives, and worked with course and clerkship directors to develop and enhance educational strategies and implement a longitudinal curricular thread woven across all four years of medical school curriculum. Conclusion: Development and implementation of a comprehensive addiction curriculum is feasible, and this model could lay the ground work for implementation at other institutions.
- 28 February 2019
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 43 (5) , 937-944
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Background: This study is the first to examine longitudinal posttreatment outcomes of a placebo‐controlled trial of varenicline for alcohol use disorder (AUD) with comorbid cigarette smoking.Methods: Participants were 131 adults (n = 39 female) seeking alcohol treatment in a randomized, double‐blind, parallel group, placebo‐controlled, 16‐week multisite trial of varenicline combined with medical management (MM). Timeline follow‐back assessments of alcohol and smoking behavior were conducted at the end of treatment (4 months), with follow‐ups at 6, 9, and 12 months. Outcomes were percentage of heavy drinking days (PHDD), percent of participants with no heavy drinking days (NHDD), cotinine‐confirmed prolonged smoking abstinence (PA), and good clinical outcome on either NHDD or PA.Results: Treatment improvements were maintained posttreatment. For the sample overall, PHDD or NHDD did not differ significantly by treatment condition (ps > 0.13), but varenicline produced higher rates of PA versus placebo at 4, 9, and 12 months (p < 0.05). Significant differences were observed by sex: Males had higher rates of NHDD with varenicline (28.9%) versus placebo (6.4%) at the end of treatment (p = 0.004), and these effects were maintained at 12 months (varenicline: 40.0% vs. placebo: 19.2%, p = 0.03). Higher rates of PA were seen for varenicline in both males (8.9%) and females (21.1%) versus placebo (males/females: 0%) at the end of treatment (p = 0.05), and this effect was maintained at 12 months for females (varenicline: 21.1% vs. placebo, 0.0%, p = 0.05).Conclusions: Varenicline treatment combined with MM appears to have enduring benefits for patients with co‐occurring AUD and cigarette smoking, and these effects may differ by sex.
- 28 February 2019
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 43 (5) , 937-944
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Background: This study is the first to examine longitudinal posttreatment outcomes of a placebo‐controlled trial of varenicline for alcohol use disorder (AUD) with comorbid cigarette smoking.Methods: Participants were 131 adults (n = 39 female) seeking alcohol treatment in a randomized, double‐blind, parallel group, placebo‐controlled, 16‐week multisite trial of varenicline combined with medical management (MM). Timeline follow‐back assessments of alcohol and smoking behavior were conducted at the end of treatment (4 months), with follow‐ups at 6, 9, and 12 months. Outcomes were percentage of heavy drinking days (PHDD), percent of participants with no heavy drinking days (NHDD), cotinine‐confirmed prolonged smoking abstinence (PA), and good clinical outcome on either NHDD or PA.Results: Treatment improvements were maintained posttreatment. For the sample overall, PHDD or NHDD did not differ significantly by treatment condition (ps > 0.13), but varenicline produced higher rates of PA versus placebo at 4, 9, and 12 months (p < 0.05). Significant differences were observed by sex: Males had higher rates of NHDD with varenicline (28.9%) versus placebo (6.4%) at the end of treatment (p = 0.004), and these effects were maintained at 12 months (varenicline: 40.0% vs. placebo: 19.2%, p = 0.03). Higher rates of PA were seen for varenicline in both males (8.9%) and females (21.1%) versus placebo (males/females: 0%) at the end of treatment (p = 0.05), and this effect was maintained at 12 months for females (varenicline: 21.1% vs. placebo, 0.0%, p = 0.05).Conclusions: Varenicline treatment combined with MM appears to have enduring benefits for patients with co‐occurring AUD and cigarette smoking, and these effects may differ by sex.
- 1 February 2019
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 76 (2) , 107-108
What Role Should Psychiatrists Have in Responding to the Opioid Epidemic?
This Viewpoint expresses concerns about the workforce available to care for patients with opioid use disorders and advises that psychiatrists become trained in
- 1 February 2019
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 76 (2) , 107-108
What Role Should Psychiatrists Have in Responding to the Opioid Epidemic?
This Viewpoint expresses concerns about the workforce available to care for patients with opioid use disorders and advises that psychiatrists become trained in
- 21 March 2016
- Published by Springer Nature in Academic Psychiatry
- Vol. 40 (3) , 494-497
An Innovative Use of Case Conference to Teach Future Educators in Addiction Psychiatry
Objective An innovative course was developed for fellows enrolled in the Yale School of Medicine Addiction Psychiatry program to educate them in key principles of adult learning, apply these principles in a case conference presentation, and to improve skills in providing and receiving feedback. Methods An initial training module on educational skills was followed by individual mentorship to prepare a case presentation. A feedback module provided space to learn and practice skills in feedback delivery. Results The program showed positive results and improved confidence levels of the participants in presenting and providing/receiving feedback. Conclusions Implementing a course designed to improve teaching and feedback skills is feasible in a 1-year Addiction Psychiatry fellowship.
- 21 March 2016
- Published by Springer Nature in Academic Psychiatry
- Vol. 40 (3) , 494-497
An Innovative Use of Case Conference to Teach Future Educators in Addiction Psychiatry
Objective An innovative course was developed for fellows enrolled in the Yale School of Medicine Addiction Psychiatry program to educate them in key principles of adult learning, apply these principles in a case conference presentation, and to improve skills in providing and receiving feedback. Methods An initial training module on educational skills was followed by individual mentorship to prepare a case presentation. A feedback module provided space to learn and practice skills in feedback delivery. Results The program showed positive results and improved confidence levels of the participants in presenting and providing/receiving feedback. Conclusions Implementing a course designed to improve teaching and feedback skills is feasible in a 1-year Addiction Psychiatry fellowship.